Incidence rate and risk factors for loss to follow-up in HIV-infected patients from five French clinical centres in Northern France - January 1997 to December 2006

Antiviral Therapy

Volumn 14, Issue 4, 2009, Pages 567-575

  Ndiaye, Bakhao ^a,b,c   Ould Kaci, Karim ^a   Salleron, Julia ^b   Bataille, Pierre ^c,d   Bonnevie, Frederique ^e,f   Choisy, Philippe ^c,g   Cochonat, Karine ^c,h   Fontier, Clotilde ^c,f   Guerroumi, Habib ^g   Ajana, Faiza ^c,g   Chaud, Pascal ^a   Yazdanpanah, Yazdan ^b,c,g  

^a CIRE Nord   (France)

^b UNIV LILLE   (France)

^c Nord Pas de Calais ^*  (France)

^d Centre Hospitalier de Boulogne   (France)

^e Centre Hospitalier de Dunkerque   (France)

^f CENTRE HOSPITALIER DE VALENCIENNES   (France)

^g Service Universitaire des Maladies Infectieuses et du Voyageur   (France)

^h Centre Hospitalier de LENS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW UP; FRANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VIRUS LOAD; VIRUS TRANSMISSION; AGE; PATIENT; SUBSTANCE ABUSE;

ADULT; AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FOLLOW-UP STUDIES; FRANCE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PATIENT DROPOUTS; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 68549097943     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Mocroft A, Vellä S, Benfield TI, et al. Changing patterns of mortality across-Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
2. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356:291-296.
3. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
4. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315:1194-1199.
5. Dalal RP, Macphail C, Mqhayi M, et al. Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2008; 47:101-107.
6. Karcher H, Omondi A, Odera J, et al. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health 2007; 12:687-694.
7. Maru DS, Khakha DC, Tahir M, et al. Poor follow-up rates at a self-pay northern Indian tertiary AIDS clinic. Int J Equity Health 2007; 6:14.
8. Maskew M, MacPhail P, Menezes C, et al. Lost to follow up: contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J 2007; 97:853-857.
9. Boarts JM, Bogart LM, Tabak MA, et al. Relationship of race-, sexual orientation-, and HIV-related discrimination with adherence to HIV treatment: a pilot study. J Behav Med 2008; 31:445-451.
10. Elion R, Cohen C, Ward D, et al. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily. HIV Clin Trials 2008; 9:213-224.
11. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999; 13 Suppl 1:S61-S72.
12. Fumaz CR, Munoz-Moreno JA, Molto J, et al. Sustained antiretroviral treatment adherence in survivors of the re-HAART era: attitudes and beliefs. AIDS Care 2008; 20:796-805.
13. Plankey M, Bacchetti P, Jin C, et al. Self-perception of body fat changes and HAART adherence in the Women's Interagency HIV Study. AIDS Behav 2009; 13:53-59.
14. Roux P, Carrieri MP, Villes V, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF 2000 cohort study. Addiction 2008; 103:1828-1836.
15. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004; 36:808-816.
16. Mocroft A, Kirk O, Aldins P, et al. Loss to follow-up in an international, multicentre observational study. HIV Med 2008; 9:261-269.
17. Lanoy E, Mary-Krause M, Tattevin P, et al. Predictors identified for losses to follow-up among HIV-seropositive patients. J Clin Epidemiol 2006; 59:829-835.
18. Nacher M, El Guedj M, Vaz T, et al. Risk factors for follow-up interruption of HIV patients in French Guiana. Am J Trop Med Hyg 2006; 74:915-917.
19. Lebouche B, Yazdanpanah Y, Gerard Y, et al. Incidence rate and risk factors for loss to follow-up in a French clinical cohort of HIV-infected patients from January 1985 to January 1998. HIV Med 2006; 7:140-145.
20. Yazdanpanah Y, Chene G, Losina E, et al. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol 2001; 30:864-871.
21. Commission Nationale d'Information et de Libertés. [National death index registries]. (Updated 24 September 2008. Accessed November 2008) French. Available from http://www.cnil.fr/index.php?id=1804&print=1
22. Ancelle-Park R. Expanded European AIDS case definition. Lancet 1993; 341:441.
23. Delfraissy JF. Prise en charge thérapeutique des personnes infectées par le VIH. (Updated 20 Feburary 2004. Accessed 24 September 2008.) Available from http://www.sante.gouv.ft/htm/actu/ delfraissy_2004/rapport.pdf
24. Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994; 14:52-58.
25. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Series B Stat Methodol 1972; 34:269-276.
26. Therneau TM, Grambsch PM. In modelling survival data: extending the Cox model. Springer 2000; pp. 69.
27. Shoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982; 69:239-241.
28. SAS Institute, Inc. SAS/SAT Guide for Personal Computers. Cary, NC: SAS Institute 1993.
29. Arici C, Ripamonti D, Maggiolo F, et al. Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clin Trials 2002; 3:52-57.
30. Conseil National du Sida. Rethinking the response to HVI/AIDS in the overseas departments. Recommendations for the strategy against HIV/AIDS in the overseas departments. (Updated 30 April 2009. Accessed October 2008.) Available from http://www.cns.sante.fr/ spip.php?article210&decoupe_recherche=rethinking&lang=en
31. Ioannidis JP, Bassett R, Hughes MD, et al. Predictors and impact of patients lost to follow-up in a long-term randomized trial of immediate versus deferred antiretroviral treatment. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:22-30.
32. Messiah A, Navaline H, vis-Vogel A, et al. Sociodemographic and behavioral characteristics associated with timeliness and retention in a 6-month follow-up study of high-risk injection drug users. Am J Epidemiol 2003; 157:930-939.
33. Chan AC, Palepu A, Guh DP, et al. HIV-positive injection drug users who leave the hospital against medical advice: the mitigating role of methadone and social support. J Acquir Immune Defic Syndr 2004; 35:56-59.
34. Deyo RA, Inui TS. Dropouts and broken appointments. A literature review and agenda for future research. Med Care 1980; 18:1146-1157.
35. Catz SL, McClure JB, Jones GN, et al. Predictors of outpatient medical appointment attendance among persons with HIV. AIDS Care 1999; 11:361-373.
36. Haddow LJ, Edwards SG, Sinka K, et al. Patients lost to follow up: experience of an HIV clinic. Sex Transm Infect 2003; 79:349-350.
37. Cohen CJ, Iwane MK, Palensky JB, et al. A national HIV community cohort: design, baseline, and follow-up of the AmFAR Observational Database. American Foundation for AIDS Research Community-Based Clinical Trials Network. J Clin Epidemiol 1998; 51:779-793.
38. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration, ART Cohort Collaboration (ART-CC). Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.